title: Colorectal clinical trials: what is on the horizon?
abstract: Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 460 W 10th Ave., Columbus, OH 43210, USA.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Ahn
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, 460 W 10th Ave., Columbus, OH 43210, USA.
authors.forename: Richard M
authors.initials: RM
authors.lastname: Goldberg
mesh_terms: D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D015398:Signal Transduction / Q000187:drug effects
keywords: colorectal cancer; immunotherapy; next-generation sequencing; targeted therapy